Contents & References of Evaluation of the effects of some peptides binding to Trk B receptor on Sk-ov-3 and Ov-car-3 cell lines
List:
Cancer. 6
Cancer treatment. 8
TrkB receptor and its function. 9
Trk B and cancer. 11
Structure of Trk B. 12
Trk receptor binding sites. 13
Neurotrophic factors and their function 13
BDNF protein and its function. 15
Trk B inhibitor drugs. 17
Peptide therapy. 17
Bioinformatics. 28
Flow cytometry. 29
Western Blot 30
Materials and methods 32
Peptide library design. 33
Creation of flexible peptide skeletons. 34
Classification of produced peptides based on energy. 35
Selecting the best peptides based on energy. 36
Creating the three-dimensional structure of the most stable peptides 36
Connection of the designed peptides with Trk B receptor. 36
Investigation of peptide and receptor interactions. 38
Laboratory section. 38
Solutions 38
Cell culture. 38
Cellular passage (sub-culture) 39
Adherent cells. 39
Suspant cells. 40
Freeze. 40
Decomplemented FBS preparation method for use in cell culture. 41
To melt. 41
Cell counting. 41
MTT Assay. 42
Used concentrations for peptide. 43
Flow cytometry. 43
Protein extraction. 44
Materials used to harvest cells. 45
Protein measurement by Bradford method. 47
Steps of western blotting. 47
SDS-PAGE gel preparation 48
Preparation of proteins for loading in SDS-PAGE. 50
Transfer step. 51
Preparation of solutions. 52
Preparation of pvdf paper 53
Blotting step. 53
Peptide library design. 55
IC50% of cells 57
3D structure prediction. 58
ligand-receptor interaction. 59
Amino acids participating in the interaction. 61
Showing interactions of Trk B receptor with designed peptides. 62
Investigating the toxic effect of synthesized peptides by cell survival test. 65
Flow cytometry results. 71
Western blot results. 77
Peptide and receptor interactions. 79
Discussion. 82
Sources 90
Source:
1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA: A Cancer Journal for Clinicians. 2011;61(4):212-36.
2. Rodu B, Cole P. The fifty-year decline of cancer in America. Journal of clinical oncology. 2001;19(1):239-41.
3. McPhee SJ, Papadakis MA, Rabow MW. Current medical diagnosis & treatment 2010: McGraw-Hill Medical; 2010.
4. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. International Journal of Cancer. 1975;15(4):617-31.
5. Ames BN. Identifying environmental chemicals causing mutations and cancer. Jurimetrics J. 1979;20:326.
6. Hill M, Hawksworth G, Tattersall G. Bacteria, nitrosamines and cancer of the stomach. British journal of cancer. 1973;28(6):562.
7. Issenberg P, editor. Nitrite, nitrosamines, and cancer. Federation proceedings; 1976.
8. Struewing JP, Hartge P, Wachholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New England Journal of Medicine. 1997;336(20):1401-8.
9. Ford D, Easton D, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. American journal of human genetics. 1998;62(3):676.
10. Levine AJ. The tumor suppressor genes. Annual review of biochemistry. 1993;62(1):623-51.
11. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73(8):26-2013.
12. Osborne C, Wilson P, Tripathy D. Oncogenes and Tumor Suppressor Genes inOncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications. The Oncologist. 2004;9(4):361.
13. Latif F, Tory K, Gnarra J, Yao M, Duh F-M, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (New York, NY). 1993;260(5112):1317.
14. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin H, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9(6):1799.
15. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78(5):773.
16. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating the abundance of the cyclin-dependent kinase inhibitor p27. Science (New York, NY). 1995;269(5224):682.
17. Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. DNA Methylation: Development, Genetic Disease and Cancer. 2006:251-74.
18. Choi SH, Worswick S, Byun HM, Shear T, Soussa JC, Wolff EM, et al. Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. International Journal of Cancer. 2009;125(3):723-9.
19. Shao C, Lacey M, Dubeau L, Ehrlich M. Hemimethylation footprints of DNA demethylation in cancer. Epigenetics. 2009;4(3):165-75.
20. BOZKURT C, BOZKURT S, ARDA N, ERTEM AU, ?AH?N G, YUKSEK N, et al. P16 and p27 tumor suppressor gene methylation status in childhood Wilms tumor cases. TurkJMedSci. 2011;41(4):633-8.
21. Suzuki Y, Tamura G, Satodate R, Fujioka T. Infrequent Mutation of p53 Gene in Human Renal Cell Carcinoma Detected by Polymerase Chain Reaction Single?strand Conformation Polymorphism Analysis. Cancer science. 1992;83(3):233-5.
22. Lim D-S, Hasty P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Molecular and cellular biology. 1996;16(12):7133-43.
23. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer. 2002;94(9):2511-6.
24. Varricchio CG. A cancer source book for nurses: Jones & Bartlett Learning; 2004.
25. Miller A, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-14.
26. Strong LC. Genetic etiology of cancer. Cancer. 2006;40(S1):438-44.
27. Lingeman C. Etiology of cancer of the human ovary: a review. Journal of the National Cancer Institute. 1974;53(6):1603.
28. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, et al. Holland-Frei cancer medicine. 2003.
29. Alfreda L, Claudiab S, Svend G, Norbertd G, Peterb K. Complementary and alternative treatment methods in children with cancer: A population-based retrospective survey on the prevalence of use in Germany. Eur J Cancer. 2008;44:2233-40.
30. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Peptide Science. 2002;66(3):184-99.
31. Lien S, Lowman HB. Therapeutic peptides. Trends in biotechnology. 2003;21(12):556-62.
32. Shadidi M, Sioud M. Selective targeting of cancer cells using synthetic peptides. Drug resistance updates. 2003;6(6):363-71.
33. Zhang B, Zhang Y, Wang J, Zhang Y, Chen J, Pan Y, et al. Screening and identification of a targeting peptide to hepatocarcinoma from a phage display peptide library. Molecular Medicine. 2007;13(5-6):246.
34. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al.